These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 1497823)

  • 1. Liposomes in the treatment of malignancy: a clinical perspective.
    Sugarman SM; Perez-Soler R
    Crit Rev Oncol Hematol; 1992; 12(3):231-42. PubMed ID: 1497823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES; Maeda M; Jaffe N
    Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal MTP-PE.
    Gano JB; Kleinerman ES
    J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
    Kurzman ID; Shi F; Vail DM; MacEwen EG
    Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
    Kleinerman ES; Jaffe N
    Prog Clin Biol Res; 1990; 343():263-79. PubMed ID: 2198583
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
    Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
    J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.
    Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ
    Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis.
    Killion JJ; Fidler IJ
    Immunomethods; 1994 Jun; 4(3):273-9. PubMed ID: 7820457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current state of liposome-complexed drugs in the treatment of cancer patients.
    de Vries EG; Mulder NH; Daemen T
    Ann Oncol; 1992 Jun; 3(6):419-21. PubMed ID: 1498057
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs.
    Bezault J; Walsh C; Tarcsay L; Frost H; Liebes L; Furmanski P
    In Vivo; 1993; 7(6A):487-91. PubMed ID: 8193265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE) and interferon-y (IFN-y) in experimental infection with Listeria monocytogenes.
    Melissen PM; van Vianen W; Bidjai O; van Marion M; Bakker-Woudenberg IA
    Biotherapy; 1993; 6(2):113-24. PubMed ID: 8398570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome-enhanced tumour therapy in canine mammary gland tumours.
    Teske E; Rutteman GR
    Tijdschr Diergeneeskd; 1993 Mar; 118 Suppl 1():32S-33S. PubMed ID: 8480312
    [No Abstract]   [Full Text] [Related]  

  • 15. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases.
    Schroit AJ; Fidler IJ
    Prog Clin Biol Res; 1982; 102 pt A():347-55. PubMed ID: 7167445
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages.
    Utsugi T; Nii A; Fan D; Pak CC; Denkins Y; van Hoogevest P; Fidler IJ
    Cancer Immunol Immunother; 1991; 33(5):285-92. PubMed ID: 1868486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
    Phillips NC; Rioux J; Tsao MS
    Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTP-PE in liposomes as a biological response modifier in the treatment of cancer: current status.
    Frost H
    Biotherapy; 1992; 4(3):199-204. PubMed ID: 1599803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
    Gianan MA; Kleinerman ES
    Cancer Biother Radiopharm; 1998 Oct; 13(5):363-8. PubMed ID: 10851426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents.
    Killion JJ; Kleinerman ES; Wilson MR; Tanaka M; Fidler IJ
    Oncol Res; 1992; 4(10):413-8. PubMed ID: 1292756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.